Medical institutions at the forefront of innovation already using SOPHiA in Africa include:<\/p>\n
\u2022\tPharmaProcess in Casablanca, Morocco
\n\u2022\tImmCell in Rabat, Morocco
\n\u2022\tThe Al Azhar Oncology Center in Rabat, Morocco
\n\u2022\tThe Riad Biology Center in Rabat, Morocco
\n\u2022\tThe Oudayas, Medical Analysis Laboratory, Morocco
\n\u2022\tThe Center for Proteomic & Genomic Research (CPGR) in Cape Town, South Africa
\n\u2022\tThe Bonassama District Hospital in Douala, Cameroon<\/p>\n
African hospitals are adopting SOPHiA to – no matter their experience in genomic testing – get up to speed and analyse genomic data to identify disease-causing mutations in patients\u2019 genomic profiles, and decide on the most effective care. As new users of SOPHiA, they become part of a larger network of 260 hospitals in 46 countries that share clinical insights across patient cases and patient populations, which feeds a knowledge base of biomedical findings to accelerate diagnostics and care.<\/p>\n
Speaking about the adoption of SOPHiA in Africa, Jurgi Camblong, Sophia Genetics\u2019 CEO and co-founder, declared: \u201cSince inception, our vision has been to develop innovative technological solutions that analyse patients\u2019 genomic profiles to offer better diagnosis and care to the greatest number of patients, wherever they live. Today, I am very proud that SOPHiA is triggering a technological leapfrog movement in healthcare across Africa.\u201d<\/p>\n
The CEO added: \u201cBy joining our community, African hospitals are breaking down the technological barriers that prevented African patients from benefiting from the same level of genomic testing than patients from the best medical centres worldwide. This is a story about accessibility, democratisation, empowerment, and hope.\u201d<\/p>\n
Among other diseases, SOPHiA will be a key partner for African hospitals in oncology. Breast cancer, for instance, has been described as a \u201cserial killer\u201d on the continent as a lack of relevant diagnostics and personalised care means that 60% of women with breast cancer in Africa die, versus 20% in the US and EU. According to a 2012 global report from the International Prevention Research Institute, an earlier diagnostic of breast cancer could increase life expectancy by 30%. Globally, on the continent, the number of new cases of cancer every year should jump to 1.6 million by 2030. As oncology expertise might be based in different places across the globe, SOPHiA ensures that the knowledge of a specialist in Paris will, for instance, be accessible to save patients in Nairobi.<\/p>\n
Speaking about the benefits of using SOPHiA for African patients, Dr Reinhard Hiller from the South African Centre for Proteomic and Genomic Research (CPGR) commented: \u201cIn creating a first-of-its-kind Genomic Medicine offering in Africa, using SOPHiA has been beneficial because its analysis are used by a global community of genomic medicine practitioners, allowing us to offer a best-in-class service.\u201d<\/p>\n
Professor Hicham Mansour, Geneticist at the University Mohamed 1st Genetic Department – Al Azhar Oncology Center in Morocco, added: \u201cUsing SOPHiA allows us to analyse genomic data quickly and with great confidence, to better diagnose and follow up with our patients.\u201d<\/p>\n
Jurgi Camblong concluded: \u201cAfter Europe, Canada, Australia, Russia, and Latin America, the adoption of SOPHiA in Africa is perhaps the strongest evidence that the democratisation of Data-Driven Medicine is changing scale to help the highest number of patients, wherever they live across the globe.\u201d <\/p>\n
![\"f59baf21573014671ab43ab650e1e270_72dpi\"](\"http:\/\/intelligentcio.net\/africa\/wp-content\/uploads\/sites\/5\/2017\/03\/f59baf21573014671ab43ab650e1e270_72dpi.jpg\")
<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"